ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	1.85T -6.2%
Revenue (ttm)	386.46B +29.6%
Net Income	76.80B +126.3%
EPS	3,644.39 +114.6%
Shares Out	20.88M
PE Ratio	24.28
Forward PE	22.93
Dividend	500.00 (0.57%)
Ex-Dividend Date	Mar 30, 2026

Volume	44,443
Open	88,400
Previous Close	89,900
Day's Range	88,000 - 91,300
52-Week Range	82,100 - 172,100
Beta	0.31
Analysts	Strong Buy
Price Target	177,777.78 (+100.88%)
Earnings Date	Oct 27, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.

Analyst Summary

According to 9 analysts, the average rating for 237690 stock is "Strong Buy." The 12-month stock price target is ₩177,778, which is an increase of 100.88% from the latest price.

Price Target

₩177,778

(100.88% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 26, 2026

Data Sources Report a data error